Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea's Celltrion And Aprogen In Race To Sell Biosimilars In Japan

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korean biotech firms Celltrion and Aprogen are racing to bring biosimilars of Roche's oncology agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis agent Remicade (infliximab) to Japan

You may also be interested in...



Daiichi Sankyo Adds To Japan's Biosimilar Fray In Two-compound Deal

Daiichi Sankyo is teaming with virtual startup Coherus BioSciences for etanercept and rituximab.

Korea’s Celltrion Prepares Remicade Biosimilar Application For KFDA

Korea’s biosimilar frontrunner Celltrion is only one step away from the actual sales of its first biosimilar as it gears up to file for KFDA approval in February for its biosimilar of Johnson & Johnson’s rheumatoid arthritis agent Remicade.

Korea's Celltrion Not Seeking More Sales, Distribution Deals With Big Pharma

SEOUL - Seo Jung-Jin, CEO of South Korea's biosimilar front-runner Celltrion, Inc. said his company isn't looking to establish additional sales and distribution partnerships with Big Pharma

Related Content

UsernamePublicRestriction

Register

LL1132458

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel